이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

특발성 폐 섬유증 및 간질성 폐 질환 예상 결과 레지스트리 (IPF/ILD-PRO)

2026년 11월 9일 업데이트: Duke University

특발성 폐 섬유증 예상 결과(IPF-PRO) 및 진행성 표현형 예상 결과가 있는 만성 섬유화 간질 폐 질환(IPF-PRO/ILD-PRO) 레지스트리

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

연구 개요

상세 설명

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

연구 유형

관찰

등록 (추정된)

3000

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35294
        • 모병
        • University of Alabama - Birmingham
        • 수석 연구원:
          • Tejaswini Kulkarni, MD
        • 연락하다:
    • Arizona
      • Tucson, Arizona, 미국, 85721
        • 모병
        • University of Arizona
        • 수석 연구원:
          • Sally A Suliman, MD
        • 연락하다:
    • California
      • Los Angeles, California, 미국, 90033
        • 모병
        • University of Southern California
        • 연락하다:
        • 수석 연구원:
          • Toby Maher, MD
      • Los Angeles, California, 미국, 90024
        • 모병
        • University of California - Los Angeles
        • 수석 연구원:
          • John Belperio, MD
        • 연락하다:
      • Stanford, California, 미국, 94305
        • 모병
        • Stanford University
        • 수석 연구원:
          • Rishi Raj, MD
        • 연락하다:
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • 모병
        • University of Colorado
        • 수석 연구원:
          • Joyce Lee, MD
        • 연락하다:
    • Connecticut
      • New Haven, Connecticut, 미국, 06520
        • 모병
        • Yale University
        • 수석 연구원:
          • Mridu Gulati, MD
        • 연락하다:
    • Florida
      • Gainesville, Florida, 미국, 32610-3175
      • Tampa, Florida, 미국, 33606
        • 모병
        • University of South Florida
        • 수석 연구원:
          • Jose D Herazo-Maya, MD
        • 연락하다:
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모병
        • Emory University
        • 연락하다:
        • 수석 연구원:
          • Srihari Veeraraghavan, MD
      • Austell, Georgia, 미국, 30106
        • 모병
        • Piedmont Healthcare
        • 수석 연구원:
          • Amy Case, MD
        • 연락하다:
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • 모병
        • University of Chicago
        • 수석 연구원:
          • Mary Strek, MD
        • 연락하다:
      • Evanston, Illinois, 미국, 60611
        • 모병
        • Northwestern University
        • 연락하다:
        • 수석 연구원:
          • Bradford Bemiss, MD
      • Maywood, Illinois, 미국, 60153
        • 모병
        • Loyola University Health System
        • 수석 연구원:
          • Daniel Dilling, MD
        • 연락하다:
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • 종료됨
        • University of Kansas
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • 모병
        • University of Kentucky
        • 수석 연구원:
          • Girish Nair, MD
        • 연락하다:
    • Louisiana
      • New Orleans, Louisiana, 미국, 70112
        • 모병
        • Tulane University
        • 수석 연구원:
          • Joe Lasky, MD
        • 연락하다:
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모집하지 않고 적극적으로
        • University of Michigan
      • Detroit, Michigan, 미국, 48202
        • 모병
        • Henry Ford Health
        • 연락하다:
        • 수석 연구원:
          • Asif Abdul Hameed, MD
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55455
        • 모병
        • University of Minnesota
        • 연락하다:
        • 수석 연구원:
          • Hyum Kim, MD
    • Mississippi
      • Jackson, Mississippi, 미국, 39216
        • 모병
        • University of Mississippi Medical Center
        • 수석 연구원:
          • Kimberly Dobbs, MD
        • 연락하다:
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University
        • 수석 연구원:
          • Tonya Russell, MD
        • 연락하다:
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • Weill Medical College of Cornell University
        • 수석 연구원:
          • Kerri Aronson, MD
        • 연락하다:
      • New York, New York, 미국, 10016
        • 모집하지 않고 적극적으로
        • NYU Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27514
      • Durham, North Carolina, 미국, 27705
        • 모병
        • Duke University
        • 수석 연구원:
          • Lake Morrison, MD
        • 연락하다:
      • Greensboro, North Carolina, 미국, 27403
        • 모병
        • Pulmonix LLC
        • 수석 연구원:
          • Murali Ramaswamy, MD
        • 연락하다:
      • Wilmington, North Carolina, 미국, 28401
        • 종료됨
        • PMG Research
      • Winston-Salem, North Carolina, 미국, 27157
        • 모병
        • Wake Forest Baptist Health
        • 연락하다:
        • 수석 연구원:
          • Andrew Namen, MD
    • Ohio
      • Cincinnati, Ohio, 미국, 45267
        • 모집하지 않고 적극적으로
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, 미국, 44195
        • 모병
        • Cleveland Clinic
        • 수석 연구원:
          • Brian Southern, MD
        • 연락하다:
      • Columbus, Ohio, 미국, 43210
        • 모병
        • The Ohio State University
        • 연락하다:
        • 수석 연구원:
          • John Odackal
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • 모병
        • University of Oklahoma
        • 수석 연구원:
          • Jad Kebbe, MD
        • 연락하다:
    • Oregon
      • Portland, Oregon, 미국, 97220
        • 모병
        • Oregon Clinic
        • 수석 연구원:
          • David Hotchkin, MD
        • 연락하다:
    • Pennsylvania
      • Hershey, Pennsylvania, 미국, 17033
        • 모병
        • Penn State College of Medicine - Hershey
        • 수석 연구원:
          • Rebecca Bascom, MD
        • 연락하다:
      • Philadelphia, Pennsylvania, 미국, 19140
      • Philadelphia, Pennsylvania, 미국, 19144
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • 모병
        • Medical University of South Carolina
        • 수석 연구원:
          • Timothy Whelan, MD
        • 연락하다:
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University
        • 연락하다:
        • 수석 연구원:
          • Justin Hewlett, MD
    • Texas
      • Dallas, Texas, 미국, 75235
        • 모병
        • University of Texas Southwestern
        • 수석 연구원:
          • John Fitzgerald, MD
        • 연락하다:
      • Dallas, Texas, 미국, 75246
        • 모병
        • Baylor University Medical Center at Dallas
        • 수석 연구원:
          • Yolanda Mageto, MD
        • 연락하다:
      • Houston, Texas, 미국, 77030
        • 모병
        • Baylor College of Medicine
        • 수석 연구원:
          • Ivan Rosas, MD
        • 연락하다:
      • Houston, Texas, 미국, 77030
      • Houston, Texas, 미국, 77030
        • 모병
        • The University of Texas Health Science Center At Houston
        • 수석 연구원:
          • Rodeo Abrencillo, MD
        • 연락하다:
    • Utah
      • Salt Lake City, Utah, 미국, 84108
        • 모병
        • University of Utah
        • 연락하다:
        • 수석 연구원:
          • Mary Beth Langer, MD
      • Salt Lake City, Utah, 미국, 84111
        • 모병
        • Intermountain Health
        • 연락하다:
        • 수석 연구원:
          • Erin Blackstock, MD
    • Vermont
      • Colchester, Vermont, 미국, 05446
        • 모집하지 않고 적극적으로
        • University of Vermont Lung Center
    • Virginia
      • Charlottesville, Virginia, 미국, 22908
        • 모집하지 않고 적극적으로
        • University from Virginia
      • Falls Church, Virginia, 미국, 22042-3307
        • 모병
        • Inova Health Care Services
        • 연락하다:
        • 수석 연구원:
          • Jared Wilkinson, MD
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • 모집하지 않고 적극적으로
        • The Medical College of Wisconsin

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

21년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

설명

Inclusion Criteria:

  • Willing and able to provide informed consent

  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.

  • Age 21 years or older, or

  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.

    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion Criteria:

  • Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

Subjects with a non-IPF ILD diagnosis

Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

New Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Data on natural history of IPF & non-IPF chronic fibrosing ILD
기간: End of Study (3 years after last patient will be enrolled)

Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

End of Study (3 years after last patient will be enrolled)
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
기간: End of Study (3 years after last patient will be enrolled)

Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

End of Study (3 years after last patient will be enrolled)
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
기간: End of Study (3 years after last patient will be enrolled)

Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

End of Study (3 years after last patient will be enrolled)
Blood samples for future research.
기간: End of Study (3 years after last patient will be enrolled)

Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

End of Study (3 years after last patient will be enrolled)
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
기간: End of Study (3 years after last patient will be enrolled)

Collect longitudinal HRCT images for future research

End of Study (3 years after last patient will be enrolled)

2차 결과 측정

결과 측정
측정값 설명
기간
Data on management practices compared to existing guidelines.
기간: End of Study (3 years after last patient will be enrolled)

Compare disease-specific management practices with existing guidelines.

End of Study (3 years after last patient will be enrolled)
Data on center-specific practices on outcomes.
기간: End of Study (3 years after last patient will be enrolled)

Determine the influence of center-specific practices on patient outcomes.

End of Study (3 years after last patient will be enrolled)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Scott Palmer, MD, Duke Clinical Research Institute, Duke University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2014년 6월 1일

기본 완료 (추정된)

2028년 1월 1일

연구 완료 (추정된)

2031년 1월 1일

연구 등록 날짜

최초 제출

2013년 7월 31일

QC 기준을 충족하는 최초 제출

2013년 8월 1일

처음 게시됨 (추정된)

2013년 8월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다